Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on Tuesday.
Washington — Lawmakers will question the maker of popular weight loss drugs Ozempic and Wegovy during a Senate committee hearing on Tuesday focused on what Sen. Bernie Sanders has called 'outrageously high' prices Americans pay for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee, led by Sanders.
For Wegovy, the committee found that Novo Nordisk charges Americans with obesity $1,349 per month, as compared to $140 in Germany and $92 in the United Kingdom.The popular weight loss drugs, known as GLP-1 agonists, are often used by people with diabetes and obesity, and have seen soaring demand in the last year. But for 54% of adults who had taken a GLP-1 drug — even those with insurance — they said the cost was 'difficult' to afford, according to a KFF poll released in May.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic, Wegovy maker Novo Nordisk faces hearing over high cost of weight loss drugsBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Read more »
Ahead of Novo Nordisk Hearing, 250 Clinicians Demand Affordable Access to Ozempic and WegovyNewswire Editor is a Common Dreams staff position.
Read more »
Early trial shows success for daily weight loss pill: 3 things to knowThe pill is made by Novo Nordisk, the same company that makes Ozempic.
Read more »
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug pricesSen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients in other countries.
Read more »
Novo Nordisk CEO to Face Senate Grilling Over High Drug PricesThe CEO of Novo Nordisk, Lars Fruergaard Jørgensen, will testify before the Senate Health, Education, Labor and Pensions Committee on Tuesday regarding the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. Sen. Bernie Sanders, who chairs the committee, alleges that Novo Nordisk charges significantly higher prices for its drugs in the US compared to other countries.
Read more »
Novo Nordisk weight-loss drug is effective for kids as young as 6, study showsA drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study…
Read more »